Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Together with the cohorts described above, this project uses the infrastructure of the DPUK PET-MR Imaging network (UCL, Imperial, Cambridge, Manchester, Newcastle and Edinburgh). The study team use a new compound for PET imaging in Alzheimer’s disease - the imaging agent PI-2620 - that is in development by Life Molecular Imaging.